Anti-Tuberculosis Therapeutics Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Anti-Tuberculosis Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (Active TB, Latent TB, Others), By Diagnosis and Treatment (Diagnosis (Blood Tests, Imaging Tests, Sputum Tests, Others), Treatment (First Line of Drugs, Second Line of Drugs, others), others), By End User (Hospitals, Specialty Clinics, Homecare, others), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The global anti-tuberculosis therapeutics market is projected to expand significantly, from USD 1411.21 million in 2025 to USD 1995.04 million by 2031, achieving a compound annual growth rate of 5.94%. These therapeutics are essential pharmacological interventions designed to combat infections caused by Mycobacterium tuberculosis. This market's expansion is fundamentally propelled by the rising incidence of tuberculosis, particularly in areas with a high disease burden, alongside the urgent need for advanced treatment protocols to combat multi-drug resistant strains. Furthermore, strong government initiatives and international financial support aimed at improving global diagnosis and treatment accessibility are bolstering this demand. The World Health Organization's Global Tuberculosis Report 2024 highlighted the gravity of this situation, reporting that approximately 10.8 million people contracted tuberculosis in 2023, emphasizing the continuous and pressing demand for efficacious therapeutic solutions.
A primary obstacle to the market's growth is the increasing spread of antimicrobial resistance, which diminishes the effectiveness of conventional first-line antibiotics. The rise of these resistant bacterial strains compels healthcare professionals to employ second-line therapies, which typically involve higher expenses, greater toxicity, and longer treatment periods. Such characteristics often result in decreased patient compliance and impose considerable financial stress on public health infrastructures, consequently hindering the widespread adoption of existing therapeutic alternatives.
Market Driver
The significant prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis is a key driver for market expansion, demanding the use of sophisticated pharmacological agents beyond standard first-line treatments. When isoniazid and rifampicin prove ineffective, healthcare systems are prompted to acquire second-line therapeutics and innovative combinations, such as BPaL (bedaquiline, pretomanid, and linezolid), to enhance patient recovery. The World Health Organization's 'Global Tuberculosis Report 2024' (October 2024) indicated that approximately 400,000 individuals developed MDR or rifampicin-resistant tuberculosis in 2023. This critical need specifically stimulates the commercial focus on high-value, patent-protected drugs that can reduce treatment times and lessen the severe toxicities associated with older drug categories, thereby redefining revenue opportunities for companies targeting resistant strains.
Growing financial investments from both governmental and non-governmental organizations are accelerating the clinical progress of new anti-tubercular drugs and vaccines. This capital inflow diminishes the financial risks for pharmaceutical companies, nurturing a stronger pipeline of potential therapies aimed at complex infection types. The '2024 Report on TB Research Funding Trends' (December 2024) by the Stop TB Partnership and Treatment Action Group revealed that global funding for tuberculosis research and development reached US$1.2 billion in 2023. Such investments are vital for expanding manufacturing and distribution capacities to satisfy worldwide demand. Highlighting the extensive therapeutic requirement, the World Health Organization reported in 2024 that 8.2 million people were newly diagnosed with tuberculosis in 2023, marking the highest figure recorded since global monitoring began.
Market Challenge
The rising prevalence of antimicrobial resistance (AMR) poses a significant impediment to the expansion of the global anti-tuberculosis therapeutics market. As Mycobacterium tuberculosis strains increasingly resist standard first-line antibiotics, healthcare providers must turn to second-line pharmacological treatments. These alternative therapies come with substantially higher acquisition costs and more pronounced toxicity profiles than conventional treatments. As a result, this heightened financial burden severely strains public health budgets, especially in regions heavily affected by tuberculosis, restricting government programs' capacity to procure and distribute these vital medications broadly. This economic pressure, coupled with side effects that deter patient adherence, directly limits the wider commercial uptake and volume of advanced therapeutic agents.
A notable gap exists between the urgent demand for resistance-specific therapies and their actual implementation, as evidenced by recent figures. The World Health Organization reported in 2025 that only approximately two out of five individuals diagnosed with multidrug-resistant tuberculosis received the required treatment in 2024. This statistic highlights a major market constraint: despite the existence of effective second-line therapeutics, the complexities and resource demands involved in managing resistant strains prevent these products from reaching a substantial portion of the patient population needing them, thus hindering the market's potential for growth.
Market Trends
The widespread integration of BPaL and BPaLM treatment protocols is swiftly transforming the global standard of care, moving away from extended injectable regimens towards more efficient, six-month, all-oral courses. This significant operational shift enables national health systems to centralize their therapeutic supplies around bedaquiline, pretomanid, and linezolid, thereby considerably simplifying supply chain management and boosting treatment completion rates due to easier administration. The rapid pace of this implementation is redefining market demand, as demonstrated by the speed of international purchases. According to the '2024 Annual Report' by TB Alliance (January 2025), over 100,000 courses of the BPaL/M regimen were ordered across nearly 100 countries in 2024, marking the quickest therapeutic deployment in the modern history of the sector.
Concurrently, the creation of pediatric-specific dispersible drug formulations is fostering a distinct market segment dedicated to precise, child-friendly dosing. Manufacturers are progressively shifting from using fragmented adult tablets to developing pleasant, water-soluble options that guarantee accurate bioavailability for children. This emphasis on innovative formulations addresses crucial deficiencies in therapeutic adherence and safety for younger patients. Illustrating the effectiveness of these focused development efforts, interim data from the 'IMPAACT 2034' study, as reported by TB Alliance in a November 2025 press release, showed that a single dose of a novel pediatric dispersible pretomanid formulation produced pharmacokinetic exposures in children similar to those observed in adults.
Key Market Players
* AstraZeneca Plc.
* Johnson & Johnson Private Limited
* Eli Lilly and Company
* F. Hoffmann-La Roche Ltd.
* Mylan N.V.
* Teva Pharmaceutical Industries Ltd.
* Sanofi SA
* Novartis AG
* Sun Pharmaceutical Industries Ltd.
* Merck & Co., Inc.
Report Scope
In this report, the Global Anti-Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Anti-Tuberculosis Therapeutics Market, By Disease Type
* Active TB
* Latent TB
* Others
# Anti-Tuberculosis Therapeutics Market, By Diagnosis and Treatment
* Diagnosis
* Treatment
* others
# Anti-Tuberculosis Therapeutics Market, By End User
* Hospitals
* Specialty Clinics
* Homecare
* others
# Anti-Tuberculosis Therapeutics Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Anti-Tuberculosis Therapeutics Market.
Available Customizations:
Global Anti-Tuberculosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Anti-Tuberculosis Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type (Active TB, Latent TB, Others)
5.2.2. By Diagnosis and Treatment (Diagnosis (Blood Tests, Imaging Tests, Sputum Tests, Others), Treatment (First Line of Drugs, Second Line of Drugs, others), others)
5.2.3. By End User (Hospitals, Specialty Clinics, Homecare, others)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Anti-Tuberculosis Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Diagnosis and Treatment
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Anti-Tuberculosis Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease Type
6.3.1.2.2. By Diagnosis and Treatment
6.3.1.2.3. By End User
6.3.2. Canada Anti-Tuberculosis Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease Type
6.3.2.2.2. By Diagnosis and Treatment
6.3.2.2.3. By End User
6.3.3. Mexico Anti-Tuberculosis Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease Type
6.3.3.2.2. By Diagnosis and Treatment
6.3.3.2.3. By End User
7. Europe Anti-Tuberculosis Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Diagnosis and Treatment
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Anti-Tuberculosis Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Diagnosis and Treatment
7.3.1.2.3. By End User
7.3.2. France Anti-Tuberculosis Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Diagnosis and Treatment
7.3.2.2.3. By End User
7.3.3. United Kingdom Anti-Tuberculosis Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Diagnosis and Treatment
7.3.3.2.3. By End User
7.3.4. Italy Anti-Tuberculosis Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease Type
7.3.4.2.2. By Diagnosis and Treatment
7.3.4.2.3. By End User
7.3.5. Spain Anti-Tuberculosis Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease Type
7.3.5.2.2. By Diagnosis and Treatment
7.3.5.2.3. By End User
8. Asia Pacific Anti-Tuberculosis Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Diagnosis and Treatment
8.2.3. By End User
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Anti-Tuberculosis Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Diagnosis and Treatment
8.3.1.2.3. By End User
8.3.2. India Anti-Tuberculosis Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Diagnosis and Treatment
8.3.2.2.3. By End User
8.3.3. Japan Anti-Tuberculosis Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Diagnosis and Treatment
8.3.3.2.3. By End User
8.3.4. South Korea Anti-Tuberculosis Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease Type
8.3.4.2.2. By Diagnosis and Treatment
8.3.4.2.3. By End User
8.3.5. Australia Anti-Tuberculosis Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease Type
8.3.5.2.2. By Diagnosis and Treatment
8.3.5.2.3. By End User
9. Middle East & Africa Anti-Tuberculosis Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Diagnosis and Treatment
9.2.3. By End User
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Anti-Tuberculosis Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Diagnosis and Treatment
9.3.1.2.3. By End User
9.3.2. UAE Anti-Tuberculosis Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Diagnosis and Treatment
9.3.2.2.3. By End User
9.3.3. South Africa Anti-Tuberculosis Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Diagnosis and Treatment
9.3.3.2.3. By End User
10. South America Anti-Tuberculosis Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease Type
10.2.2. By Diagnosis and Treatment
10.2.3. By End User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Anti-Tuberculosis Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease Type
10.3.1.2.2. By Diagnosis and Treatment
10.3.1.2.3. By End User
10.3.2. Colombia Anti-Tuberculosis Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease Type
10.3.2.2.2. By Diagnosis and Treatment
10.3.2.2.3. By End User
10.3.3. Argentina Anti-Tuberculosis Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease Type
10.3.3.2.2. By Diagnosis and Treatment
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Anti-Tuberculosis Therapeutics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. AstraZeneca Plc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Johnson & Johnson Private Limited
15.3. Eli Lilly and Company
15.4. F. Hoffmann-La Roche Ltd.
15.5. Mylan N.V.
15.6. Teva Pharmaceutical Industries Ltd.
15.7. Sanofi SA
15.8. Novartis AG
15.9. Sun Pharmaceutical Industries Ltd.
15.10. Merck & Co., Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們